DCGI pulls up Glenmark for false claim on Favipiravir

Updated : July 19, 2020 01:56 PM IST

DCGI issued notices based on a representation by a Member of Parliament (MP), who complained about the cost of the drug and the false claims.

Fabiflu is the generic version of Favipiravir, which was approved by DCGI for treating mild COVID-19 patients in June.

Glenmark initially fixed the price of the Fabiflu at Rs 103 per tablet, taking the overall cost of the 14-day regimen that includes 122 tablets to Rs 12,500.

The Drug Controller General of India (DCGI) issued notices to Glenmark seeking clarification from the company regarding the false claim that its antiviral drug Fabiflu, is effective on COVID-19 patients with co-morbidities.

"It has been mentioned in representation that Glenmark has claimed that this drug is effective in co-morbid conditions like hypertension, diabetes whereas in reality, as per protocol summary, this trial was not designed to assess the Fabiflu in co-morbid conditions. No clinically sufficient data specific to these conditions are available," said VG Somani, DCGI in the notice to the company.

Fabiflu is the generic version of Favipiravir, which was approved by DCGI for treating mild COVID-19 patients in June.

DCGI issued notices based on a representation by a Member of Parliament (MP), who complained about the cost of the drug and the false claims.

Glenmark initially fixed the price of the Fabiflu at Rs 103 per tablet, taking the overall cost of the 14-day regimen that includes 122 tablets to Rs 12,500. The company last week dropped the prices to Rs 75 per tablet that brought the cost down to Rs 9,150.

The MP said that the cost proposed by Glenmark is definitely not in the interest of the poor, lower middle class and middle-class people.

(Source: MoneyControl.com)

Published : July 19, 2020 01:56 PM IST

DCGI pulls up Glenmark for false claim on Favipiravir

You May Also Like

Closing Bell: Sensex, Nifty end flat as IT gains, banks drag; markets down around 1.5% for the week

Q4 Portfolio changes: Rakesh Jhunjhunwala cuts stake in 3 firms, adds in 1; Check out

ALCOA's strong Q1CY21 augurs well for Hindalco, NALCO, Vedanta; here's why

Trending on CNBC-TV18

recommended for you